SCHEMBL10144284

SCHEMBL10144284

CCCCCCc1csc2cc(C(C)=O)sc12

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 6/20 0.80
ALOX5 P09917 2/20 0.38
TSHR P16473 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
TYR P14679 2/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38
HTT P42858 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYSLTR2 Q9NS75 2/20 0.36
CYSLTR1 Q9Y271 2/20 0.36
THRA P10827 1/20 0.35
THRB P10828 1/20 0.35
CA2 P00918 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11023679 0.89 GPR35 (1.00) GPR35ALOX5TSHRMEN1KMT2A
SCHEMBL406954 0.89 GPR35 (1.00) GPR35ALOX5TSHRMEN1KMT2A
SCHEMBL11885373 0.88 GPR35 (0.78) GPR35ALOX5TSHRMEN1KMT2A
SCHEMBL11022449 0.88 GPR35 (0.78) GPR35ALOX5TSHRMEN1KMT2A
SCHEMBL28423391 0.77 GPR35 (0.62) GPR35ALOX5TSHRMEN1KMT2A
SCHEMBL12704403 0.76 GPR35 (0.75) GPR35ALOX5TSHRMEN1KMT2A
SCHEMBL23668753 0.75 GPR35 (0.60) GPR35ALOX5TSHRMEN1KMT2A
SCHEMBL23066225 0.74 GPR35 (0.59) GPR35ALOX5TSHRMEN1KMT2A
SCHEMBL13961905 0.73 GPR35 (0.59) GPR35ALOX5TSHRMEN1KMT2A
SCHEMBL11024602 0.73 GPR35 (0.58) GPR35ALOX5TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120295965-A1 FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER CORNING INCORPORATED 2012-11-22 US disclosed
US-20120022116-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX CORNING INCORPORATED 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022116-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX GPR35, GPR65, GPR68 GPR35 1/4885ALOX5 943/4885TSHR 1910/4885
US-20120295965-A1 FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER EGFR, ERBB2, KDR GPR35 1127/4885ALOX5 4441/4885TSHR 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.